FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma By Ogkologos - October 27, 2025 339 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline EMA Recommends Extension of Indications for Datopotamab Deruxtecan MOST POPULAR Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip Castle July 20, 2021 Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer June 24, 2020 Dad Is Making Baby Giggle, But When He Makes A Sheep... May 21, 2019 Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases August 26, 2019 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΠΑΧΕΩΣ ΕΝΤΕΡΟΥ Woman with Breast Cancer May Have Saved Her Twin’s Life by... Ability of Deep Learning to Accurately Diagnose Frequent STS Subtypes from... No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in...
